A coding-independent function of an alternative Ube3a transcript during neuronal development Nat. Neurosci. May 2015
Podocalyxin promotes glioblastoma multiforme cell invasion and proliferation by inhibiting angiotensin-(1-7)/Mas signaling Oncol. Rep. May 2015
Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype Med. Oncol. May 2015
The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-?B pathway Arthritis Res. Ther. May 2015
KCNA3 Other names: HGK5; HLK3; HPCN3; HUKIII; KV1.3; MK3; PCN3
2 x 1 mL frozen cell vials each containing 1 x 10E6 cells
Negative by DNA staining and direct culture methods (ATTC - detailed information available upon request)
Cell Line Validation:
Gene expression: qPCR experiments determined specific over-expression of KNA3A.Figure 1.
Functional validationThe basic biophysical properties, expression levels, and pharmacology of Kv1.3-CHL cells were assessed using the IonWorks planar array electrophysiology platform.
Current-voltage relationship. Figure 2
Expression statistics. Figure 3
Pharmacology (Figure 4) - Inhibition of hKv1.3 K+ currents by known K+ channel blockers.
Kv1.3 is a voltage-gated K+ channel that contributes to the delayed rectifier K+ current in a range of cell types. Kv1.3 is potently blocked by the peptides ShK, charybdotoxin and margatoxin and small molecules such as PAP-1.Selective blockers of Kv1.3 inhibit calcium signaling, cytokine production and proliferation of T lymphocytes in vitro and ameliorate disease in animal models of multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus and contact dermatitis.
Figure 1: In a SYBR green qPCR experiment, specific over-expression of KCN3A was determined using gene specific primers. Data are shown as fold over-expression after normalization against GAPDH
Figure 2: Current-voltage relationship for hKv1.3 channels stably expressed in CHL cells (A); filled circles - CHL-Kv1.3, filled triangles - CHL-wild type cells. Representative recordings from CHL-Kv1.3 (B) and CHL-wild type cells (C). Experiments were conducted from a holding potential of -80mV. The depolarising step length was 200ms.
Figure 3: Expression profile: outward K+ currents of >0.6 nA were observed in 337 of 341 cells (99%), with a mean amplitude of 2.60 ± 0.132 nA (n=341; mean ± S.D.). The peak current in each cell, evoked from a depolarising pulse to +40 mV, was divided into 0.2 nA bins to create the population histogram
Figure 4: Summary pharmacology of hKv1.3-CHL cell line. Voltage-clamp recordings were made using repeated gating steps, Vh -80mV, Vstep +40mV, 1 Hz, pulse duration 250ms. Control traces in black, test compounds in red. IC50 values were obtained by fitting concentration-response curves to values for inhibition of the 1st (peak and sustained) and 5th pulse in the train (µM, shown in table). Use-dependent and open channel block can be assessed within this protocol.